Q32 Bio, Inc. (QTTB)
7.99
-0.12
(-1.48%)
USD |
NASDAQ |
Oct 07, 16:00
8.00
+0.01
(+0.13%)
After-Hours: 20:00
Q32 Bio Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2025 | 99.83% |
| September 30, 2025 | |
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | 93.33% |
| June 30, 2023 | 96.13% |
| March 31, 2023 | 95.69% |
| December 31, 2022 | 21.07% |
| September 30, 2022 | 20.82% |
| June 30, 2022 | 2.00% |
| March 31, 2022 | 32.04% |
| Date | Value |
|---|---|
| December 31, 2021 | -198.6% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 53.39% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | 72.58% |
| Beam Therapeutics, Inc. | -1.00K% |
| Prime Medicine, Inc. | -54.68% |
| Prelude Therapeutics, Inc. | 93.81% |
| Twist Bioscience Corp. | 52.76% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 103.3% |
| Return on Assets | 46.25% |
| Return on Invested Capital | 72.33% |
| Return on Net Operating Assets | 420.9% |